Immuno-Oncology Drugs Are Used For Boosting The Immune System And Destroying Cancerous Cells
Immuno-oncology uses medical
treatments that harness the power of the immune system to fight cancer. These
treatments can include cancer vaccines, checkpoint inhibitors, CAR-T cell
therapy, dendritic cell therapy and other therapies that boost the body’s
natural immune defenses.
Immuno-oncology
is based on the understanding of how tumors are formed by coevolving groups of
interactive cancer cells and immune cells. The tumor microenvironment contains
many factors that prevent the immune response from eliminating cancer cells and
promoting long-term control of cancer.
Immunotherapy uses the body’s immune system to
fight cancer and has shown promising results in many patients. There are two
major types of immunotherapy: T cell therapy and immune checkpoint blockade.
Immunotherapy uses the body’s natural immune
system to improve on its ability to detect and fight cancerous cell growth. It
is often used in combination with other treatments such as chemotherapy or
radiation.
The immune system has receptor proteins that
help distinguish healthy cells from invading cells. Sometimes these proteins
become mutated to allow cancer cells to escape from the immune system. Some
immunotherapy drugs block the proteins, thereby helping the immune system
recognize cancer cells and attack them.
Other Immuno-Oncology Drugs change
the normal cells around tumors so they are less likely to evade the immune
system. Still others target specific features of cancer cells such as
microsatellite instability-high (MSI-H), which indicates that a tumor may have
a mutation that is responsive to immunotherapy.
Immunotherapy works by enhancing the immune
system’s ability to recognize and destroy cancer cells. It uses vaccines,
monoclonal antibodies and cellular therapies such as CAR T-cell therapy, to
target specific parts of the immune system and improve the body’s natural
response to fight cancer.
Astellas Pharma Inc., has
submitted a New Drug Application for zolbetuximab to Japan's Ministry of Health, Labour and Welfare,
in June 2023. If it is approved, then this will be first LDN18.2-targeted
therapy in Japan.
Comments
Post a Comment